Analysts have turned bullish on Biocon’s strong performance for the fourth quarter ended March 2012. This has been the first strong performance of the company after eight consecutive weak quarters. Part of the reason for the strong growth is the weak base over the last eight quarters.

><table width='100%' border=0 cellspacing=0><tr><td style='FONT-FAMILY: Arial; FONT-SIZE: 18px; FONT-WEIGHT: bold; COLOR: #0253B7;'>Web view: Analysts upbeat on Biocon's Q4 numbers</td></tr><tr><tr><td style='FONT-FAMILY: Arial; FONT-SIZE: 11px; '>HSBC upgrades stock to 

Web view: Analysts upbeat on Biocon's Q4 numbers

HSBC upgrades stock to overweight with price target of Rs 270, Deutsche marginally hikes price target to Rs 220

More From This Section

Web view: ITC rides high on the predictability factor

Flexible gains

PMS managers eye trust structures

Volume concerns surround GAIL

Explore News